Digital Therapeutics (DTx) Reimbursement (DiGA & PECAN)
Introduction
Unlocking public health insurance reimbursement for Digital Therapeutics (DTx) in Europe requires navigating fast-track pathways like Germany's DiGA (BfArM) and France's PECAN (ANS/HAS). Beyond proving clinical efficacy, regulatory approval hinges on passing strict data privacy and cybersecurity audits—including GDPR compliance, Germany's Anlage 1 data security criteria, and French HDS cloud hosting rules.
Chino.io provides end-to-end technical infrastructure and regulatory alignment, helping DTx companies clear privacy hurdles, pass national audits, and bring reimbursed software to market faster.
DiGA vs. PECAN requirements
How DTx Vendors Achieve Fast-Track Reimbursement
To secure fast-track reimbursement across key European markets, Digital Therapeutics (DTx) vendors must execute a synchronized strategy spanning clinical, technical, and regulatory hurdles. First, manufacturers must complete rigorous clinical evaluations that explicitly prove positive care effects or direct medical benefits for patients.
Next, platforms must clear exhaustive data privacy and cybersecurity audits—verifying compliance with foundational standards like GDPR and ISO 27001, alongside strict national requirements such as Germany's Anlage 1 checklist or France's HDS certification.
Finally, engineering teams must ensure seamless Electronic Health Record (EHR) interoperability by implementing standardized data exchange formats like FHIR and HL7, enabling frictionless adoption into existing clinical workflows.
- Complete clinical evaluation demonstrating positive care effects or medical benefits.
- Pass data privacy and cybersecurity audits covering GDPR, ISO 27001, and country-specific health data rules.
- Ensure EHR interoperability (FHIR / HL7) for seamless clinical workflow integration.